A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to examine the pharmacokinetics (the process by which a
drug is absorbed, distributed, metabolized, and eliminated by the body) of micafungin when it
is given at 5mg/kg dose to immunocompromised children as anti-fungal prophylaxis. These
children are at high risk for developing invasive fungal disease due to their compromised
immunity and associated variable degree and duration of neutropenia. Currently, children who
receive micafungin are given daily or alternate day dosing. The investigators will give a ONE
TIME dose of micafungin and draw PK levels up to 96 hours post-infusion. The investigators
goal is to obtain comparable micafungin drug concentrations at the end of 96 hours (4 days)
as compared to lower dose at every 24 hour dosing. The investigators dosing proposal is
likely to be effective prophylaxis for immunocompromised patients and would broaden its
applicability to larger populations.